PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026International Journal of Rheumatic Diseases0 citationsOpen Access

Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non‐Biologic Treatment: Results From an Overlap Weighting Analysis in High‐Risk Patients With Axial Spondyloarthritis

View Full Paper
NHNigil HaroonZBZeynep BaskurtTCTina Hiu Tung Chim

Key Points

  • The aim is to evaluate the effectiveness of certolizumab pegol in reducing anterior uveitis flares compared to standard non-biologic treatment in high-risk patients with axial spondyloarthritis.
  • Conducted an overlap weighting analysis
  • Compared certolizumab pegol with standard non-biologic treatment
  • Focused on high-risk patients with axial spondyloarthritis
  • Certolizumab pegol significantly reduced the frequency of anterior uveitis flares
  • Improved clinical outcomes compared to standard treatment
  • Supported previous findings from the C-VIEW study

Abstract

This study supports the findings of C-VIEW and demonstrates the benefit of CZP over standard non-biologic treatment as a promising therapeutic option in reducing AAU flares among high-risk patients with axSpA.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Haroon et al. (2026) studied this question.

synapsesocial.com/papers/69cf5ecb5a333a821460d78ahttps://doi.org/10.1111/1756-185x.70621
Ask AI
Helpful
Bookmark
Share
View Full Paper